A U.S. research study of a possible COVID-19 vaccine is being expanded to consist of older adults, the age most at threat from the brand-new coronavirus.
The shot, made by the National Institutes of Health and Moderna Inc., is being evaluated in healthy young and middle-aged grownups in Seattle and Atlanta.
Moderna revealed Thursday the research study is broadening to include older adults, divided into 2 age groups– 51 to 70 and those over70
NIH stated it is looking for 60 older adults, bringing the overall being tested in the preliminary phase to 105.
Moderna also announced new financing from the U.S. government to speed advancement of the shot code-named mRNA-1273, including preparations to ramp up production and to prepare for bigger, next-step studies.
Previously today, NIH transmittable disease chief Dr. Anthony Fauci told The Associated Press the safety study was revealing “no red flags” and he hoped the next stage of screening could start around June.
The NIH shot is among three leading candidates in the global search for a vaccine.
A prospect made by CanSino Biologics has actually begun the second stage of screening in China. Another, made by Inovio Pharmaceuticals, opened its very first U.S. research study last week and simply received funding to begin similar test vaccinations in South Korea.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
